In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Antares Pharma, Inc.. Trade Record

NASDAQ:ATRS Antares Pharma, Inc. stock gains 12.45% Exit Mar 8, 2019 a Trade Record by priceseries

Trade Chart
Trade Chart ATRS Feb 22, 2019, priceSeries
About Antares Pharma, Inc.

Antares Pharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache; ZOMA-Jet and Twin-Jector, a needle-free auto injector to deliver human growth hormone treatment to children without the use of a needle; and VIBEX disposable pressure-assisted auto injectors. In addition, the company is developing VIBEX auto injectors for treating anaphylaxis; disposable pen injectors for diabetes and osteoporosis; Makena QuickShot auto injectors for reducing risk of preterm birth; and VIBEX QS Testosterone for testosterone replacement therapy for men who have testosterone deficiency. It has strategic alliances and partnership arrangements with Teva Pharmaceutical Industries, Ltd.; AMAG Pharmaceuticals, Inc.; Ferring Pharmaceuticals Inc.; and Ferring B.V. The company was founded in 1979 and is headquartered in Ewing, New Jersey.

Trade Information
Trade Type
LONG
ReliabilityScore™
88.96
Entry Date
Feb 22, 2019
Entry Price
3.22
Sell Date
Mar 8, 2019
Sell Price
3.62
Net Gain
12.45%
Hold Time
10 Trading Days